AnaptysBio, Inc. (NASDAQ:ANAB) Receives $41.45 Consensus Price Target from Analysts

AnaptysBio, Inc. (NASDAQ:ANAB) has been given an average recommendation of “Moderate Buy” by the thirteen brokerages that are currently covering the firm, Marketbeat.com reports. Four analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $40.08.

Several equities analysts recently weighed in on ANAB shares. Truist Financial decreased their target price on shares of AnaptysBio from $30.00 to $20.00 and set a “hold” rating for the company in a research note on Wednesday, December 18th. JPMorgan Chase & Co. dropped their target price on shares of AnaptysBio from $66.00 to $36.00 and set an “overweight” rating on the stock in a report on Thursday, December 19th. Wells Fargo & Company reduced their price target on AnaptysBio from $56.00 to $40.00 and set an “overweight” rating for the company in a report on Thursday, December 12th. BTIG Research lowered AnaptysBio from a “buy” rating to a “neutral” rating in a research note on Monday, December 2nd. Finally, Guggenheim cut their target price on shares of AnaptysBio from $90.00 to $36.00 and set a “buy” rating for the company in a research note on Thursday, December 12th.

Insider Activity

In other news, Director Ecor1 Capital, Llc bought 6,646 shares of the company’s stock in a transaction dated Thursday, January 2nd. The stock was bought at an average cost of $12.95 per share, for a total transaction of $86,065.70. Following the transaction, the director now owns 7,880,094 shares of the company’s stock, valued at $102,047,217.30. This represents a 0.08 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 33.70% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Values First Advisors Inc. bought a new stake in AnaptysBio during the third quarter worth $49,000. nVerses Capital LLC boosted its stake in AnaptysBio by 700.0% in the third quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock valued at $54,000 after buying an additional 1,400 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in AnaptysBio by 11.1% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,452 shares of the biotechnology company’s stock valued at $85,000 after acquiring an additional 644 shares during the last quarter. Point72 DIFC Ltd raised its stake in AnaptysBio by 680.5% during the third quarter. Point72 DIFC Ltd now owns 6,127 shares of the biotechnology company’s stock worth $205,000 after acquiring an additional 5,342 shares in the last quarter. Finally, SG Americas Securities LLC lifted its holdings in shares of AnaptysBio by 35.0% in the fourth quarter. SG Americas Securities LLC now owns 16,307 shares of the biotechnology company’s stock worth $216,000 after acquiring an additional 4,231 shares during the last quarter.

AnaptysBio Price Performance

AnaptysBio stock opened at $16.51 on Friday. The firm has a 50-day moving average of $17.23 and a 200-day moving average of $26.89. The company has a market cap of $502.40 million and a price-to-earnings ratio of -2.72. AnaptysBio has a one year low of $12.51 and a one year high of $41.31.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.72) by $0.58. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The firm had revenue of $30.02 million during the quarter, compared to the consensus estimate of $7.92 million. As a group, sell-side analysts expect that AnaptysBio will post -6.08 earnings per share for the current year.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.